Biotech | August 02, 2021
Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first batch will be shipped to the Gamaleya Center for the quality control
Subscribe To Our Newsletter & Stay Updated
